What is Sarcoma?

Posts Tagged ‘liposarcoma’

What is Sarcoma?

Sarcoma is a rare type of cancer and typically produces malignant tumors derived from the connective tissue.  There are more than 70 sarcoma types and subtypes. Soft Tissue Sarcoma Soft tissue sarcoma broadly defines cancers that develop in the body’s soft tissues (i.e. muscles, tendons, fat, lymph vessels, blood vessels, and nerves). While these cancers are most commonly found in the head, neck, arms, legs, chest, and abdomen, they can develop anywhere in the body. There are various different types of soft tissue sarcoma, and depending on the type of soft tissue the cancer started in, the cells will look…  Read More »

Meet the Researcher – Andrew Koff, PhD

Andrew Koff, PhD, Member and Professor, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center   2014 Heidi Connery Memorial Research Grant: “Proteomic and genomic approaches to understanding intrinsic and acquired resistance to CDK4 inhibition therapy in well differentiated/dedifferentiated liposarcoma”   PLEASE DESCRIBE THE FOCUS OF THE RESEARCH PERFORMED IN YOUR LAB. The laboratory of cell cycle regulation at Memorial Sloan Kettering Cancer Center is interested in identifying the genes and proteins that regulate the transition of cells from quiescence, a reversible type of proliferative exit, to senescence, a more stable irreversible type of proliferative exit.  Proliferation associated with a deregulated cell cycle…  Read More »

Sarcoma Foundation of America Applauds FDA Approval of Yondelis

-Drug Approved for Use in Treatment of Advanced Liposarcoma and Leiomyosarcoma- DAMASCUS, Md. – October 23, 2015 – The Sarcoma Foundation of America (SFA) applauds the announcement by the Food and Drug Administration (FDA) that the drug Yondelis (trabectedin, marketed by Janssen) has been approved by the agency for the treatment of advanced liposarcoma and leiomyosarcoma, two subtypes of soft tissue sarcoma. Yondelis has received approval for the use in the treatment of patients with unresectable or metastatic liposarcoma and leiomyosarcoma who have previously received an anthracycline chemotherapy. “The Sarcoma Foundation of America is thrilled with the FDA’s decision to approve…  Read More »

Welcome to our new blog!

The Sarcoma Foundation of America (SFA) is always looking for new ways to bring attention to sarcoma, and the next step in our efforts to educate the world about this little known cancer is through our new blog.  We hope that this will become a place to share inspirational stories, highlight events, and blog about the needs of sarcoma patients to find new and better treatments. So welcome to our inaugural post!  We couldn’t think of a better time to start this blog than in July – during Sarcoma Awareness Month.  While we work every single day to fulfill our…  Read More »